Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vamshikrishna Gone"'
Autor:
Valentina Z. Petukhova, Sammy Y. Aboagye, Matteo Ardini, Rachel P. Lullo, Francesca Fata, Margaret E. Byrne, Federica Gabriele, Lucy M. Martin, Luke N. M. Harding, Vamshikrishna Gone, Bikash Dangi, Daniel D. Lantvit, Dejan Nikolic, Rodolfo Ippoliti, Grégory Effantin, Wai Li Ling, Jeremy J. Johnson, Gregory R. J. Thatcher, Francesco Angelucci, David L. Williams, Pavel A. Petukhov
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Only praziquantel is available for treating schistosomiasis, a disease affecting more than 200 million people. Praziquantel-resistant worms have been selected for in the lab and low cure rates from mass drug administration programs suggest t
Externí odkaz:
https://doaj.org/article/be068dfc60f64b079ddfa79996f6b0e8
Autor:
Valentina Petukhova, Samuel Aboagye, Matteo Ardini, Rachel Lullo, Margaret Byrne, Lucy Martin, Francesca Fata, Federica Gabriele, Rodolfo Ippoliti, Wai Li Ling, Grégory Effantin, Luke Harding, Dejan Nikolic, Daniel Lantvit, Bikash Dangi, Vamshikrishna Gone, Jeremy Johnson, Gregory Thatcher, Francesco Angelucci, David Williams, Pavel Petukhov
Only one drug, praziquantel, is available for treating schistosomiasis, a disease affecting more than 200 million people. Laboratory studies have shown that schistosome worms can develop resistance to praziquantel and low cure rates from mass drug ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d86a36268bc208b4a3a9fdecfc0b73
https://hdl.handle.net/11697/194259
https://hdl.handle.net/11697/194259
Autor:
Yashaswini Akoju, Shalini Thakur, Bhuvana Chandra Pasupuleti, Nithya Valupadasu, Raj Kumar Venisetty, Vamshikrishna Gone
Bedaquiline, a novel drug was approved for the treatment of multi-drug resistance tuberculosis (MDR-TB) by the US FDA in 2012. It is majorly caused because of the transmission of multi-resistant strain from a diseased person to a healthy individual a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed8c4f9c05ad364a0431601e015166dc
https://doi.org/10.22541/au.161148453.30803063/v1
https://doi.org/10.22541/au.161148453.30803063/v1
Autor:
Om Prakash Prasad, Bhuvanachandra Pasupuleti, Vamshikrishna Gone, Raj Kumar Venisetty, Ravali Baddam
Publikováno v:
Current drug metabolism. 21(2)
Background: Clobazam (CLBZ) metabolized primarily by Cytochrome P-450 isoenzyme CYP3A4 than with CYP2C19, Whereas Levetiracetam (LEV) is metabolized by hydrolysis of the acetamide group. Few CYP enzymes are inhibited by Proton Pump Inhibitors (PPIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee403e8a055fad6a5bc373b7538e8a41
https://pubmed.ncbi.nlm.nih.gov/32067615
https://pubmed.ncbi.nlm.nih.gov/32067615